Abstract
A clinical decision report using:
Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 2015;9(6):758-769. https://doi.org/10.1016/j.jacl.2015.08.006
for a statin-intolerant patient with hyperlipidemia.
DOI
10.22237/crp/1698019740
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
KUPLICKI AC. Social determinants may limit the success of PCSK9 inhibitors, an effective treatment for hyperlipidemia in statin-intolerant patients. Clin Res Prac. Nov 1 2023;9(1):eP3264. https://doi.org/10.22237/crp/1698019740
Included in
Cardiovascular Diseases Commons, Medical Education Commons, Medical Humanities Commons, Therapeutics Commons, Translational Medical Research Commons
